

Actigraph, a Portfolio Company of Archimed, Acquired Biofourmis' Life Science Business

ActiGraph™

Acquired

Biofourmis

55th

Healthcare
Technology
Deal

30th

eClinical
Transaction

11th

Decentralized
Trials Deal

Actigraph, a Portfolio Company of Archimed, acquired Biofourmis Connect, a Division of Biofourmis, to Establish a Software and Data Ecosystem for Clinical Research Throughout the Drug-product Lifecycle and Across Therapeutic Areas

Digital health technologies, such as digital therapeutics, diagnostics, decision support tools, remote patient monitoring tools, sensor-based digital measures and AI-informed platforms offer improve patient health outcomes and provide clinical researchers more objective tools to improve safety and efficacy of therapeutics. Despite industry headwinds the past few years, new products and solutions have emerged that better meet the needs of stakeholders and deliver sustainable commercial models. Fueled by technology advancements in AI, established regulatory and reimbursement frameworks and greater acceptance among researchers, scientists, and clinicians demand for digital health technologies is increasing and platforms that delivery end-to-end solutions are emerging as winners in an increasingly, winner-take-all market opportunity. Adoption of these technologies is playing an increasingly important role in clinical research as life sciences companies face pressure to develop and commercialize new drugs and improve R&D productivity.

ActiGraph, a global leader in purpose-built, wearable digital health technology in clinical research and development has completed a transformative acquisition of Biofourmis Connect, an AI-enabled, objective digital measures and endpoints software platform for life sciences. The transaction creates a market-leading, patient-centric, software and data ecosystem for drug development. The strategic acquisition enables ActiGraph to deliver the industry's most comprehensive and trusted digital health solution, supporting a wide range of clinical use cases with a device-agnostic platform and over 30 proprietary, AI-driven algorithms. ActiGraph is further elevating its leadership in remote and real-time capture of continuous, high precision digital health data and will address new areas of high unmet need, such as objective assessments of pain and prediction of Cytokine Release Syndrome (CRS) risk in oncology and immunology trials.

Crosstree served as exclusive buy-side advisor to ActiGraph, leveraging our deep expertise in healthcare and pharma technology, data and analytics to guide the transaction to a successful outcome.

“Crosstree’s deep domain and technical expertise helps clients develop and execute growth strategies that maximize value creation synergies and create differentiated value propositions for clients”



GREG BARE

Director

gregory.bare@crosstreecapital.com

813-774-4754

Crosstree's experts are specialists in the nuances of the health sciences, prioritizing corporate core values and providing:

Deep analytics of capabilities and gaps

Systemized tactical strategies and a road map to success

Engaged experts in market analysis, financials, and premium valuations

Targeted and qualified prospects

Up-to-date industry trend analysis and forecasting

Meeting the needs of both the buyer and the seller by the numbers and beyond is Crosstree's specialty.



About ActiGraph

ActiGraph is pioneering the digital transformation of clinical research. They provide end-to-end digital health technology (DHT) solutions by integrating and operationalizing the best hardware, software, and algorithms to generate reliable evidence and get the right treatments to the right patients, faster. ActiGraph's medical-grade wearable technology platform has been used to capture real-world, continuous digital measures of activity, sleep, and mobility for nearly 250 industry-sponsored clinical trials and thousands of academic research studies. Cited in over 25,000 published scientific papers, ActiGraph is the most experienced and trusted digital health technology partner in the industry.

About Biofourmis

Biofourmis is the leader in care-at-home for hospitals, health systems, and payors. In October 2024, Biofourmis and CopilotIQ announced their strategic merger, creating the industry's first AI-driven platform that delivers in-home care across the full spectrum of pre-surgery to acute, post-acute, and chronic care. Biofourmis Care enables hospitals, health systems and payors to seamlessly extend care to patients at home across all levels of acuity. Biofourmis' data-driven solutions leverage remote monitoring devices, artificial intelligence, clinical teams and in-home services to drive clinical outcomes, improve operational efficiency, and lower costs.



Other Recent Pharma Services Transactions:

